摘要
目的：探讨地西他滨4d方案治疗骨髓增生异常综合征（MDS）的疗效及不良反应。方法：观察地西他滨4d方案（25-30mg·m-2·d-1静脉滴注，连用4d）治疗的12例MDS患者，评价其疗效及不良反应。结果：12例MDS患者完全缓解5例（41．67％），部分缓解3例（25．00％），总有效率为66．67％，中位无进展生存期为212（13～328）d，中位总生存期为255（13～963）d，主要不良反应有骨髓抑制、感染、胃肠道症状等。结论：地西他滨4d方案与3d、5d方案相比，治疗MDS的疗效确切，安全性好，应用方便，降低费用，值得进一步推广。
Objective：To assess the efficacy and adverse reaction of decitabine 4-day program treatment for myelo- dysplastic syndrome （MDS）. Method：Twelve patients with MDS were treated with decitabine 4-day program （25 to 30 mg. m-2. d- 1 ）44 days） and the clinical effect and side reaction were evaluated after every course. Result： Five cases （41.67%） had complete remission, 3 cases （25.00%） had partial remission and the overall response rate was 66.67%. The median progress free survival was 212（13 to 328）d and the median overall survival was 255 （13 to 963） d. The main adverse reactions were hone marrow suppression, infection and gastrointestinal symptoms. Conclusion：Compared with 3-day and 5-day programs, decitabine 4-day program can effectively and securely cure MDS patients. Moreover,it can avoid medicine waste and reduce cost.
出处
《临床血液学杂志》
CAS
2013年第6期792-794,共3页
Journal of Clinical Hematology
作者简介
通信作者：赵洪国，E-mail：zha06201@126．com
